Claims-Based Analysis of National Utilization Patterns and Regional Variability of Prostate Cancer Ablative Therapies: A Medicare Study
Despite expanded insurance coverage, ablative therapies remain infrequently used for prostate cancer, with substantial regional variations in their adoption. These findings highlight the need for continued data collection and outcomes evaluation to define the optimal use of ablative therapy in prostate cancer care.
Authors
- Caroline M. Moore (ORCID: https://orcid.org/0000-0003-0202-7912)
- Alexander P. Cole
- Zhiyu Qian
- Jianyi Zhang (ORCID: https://orcid.org/0000-0002-3955-6554)
- Hanna Zurl
- Adam S. Kibel (ORCID: https://orcid.org/0000-0002-9446-7781)
- Stuart R. Lipsitz (ORCID: https://orcid.org/0000-0003-2619-1389)
- Quoc‐Dien Trinh (ORCID: https://orcid.org/0000-0003-3857-9276)
- Boyuan Xiao (ORCID: https://orcid.org/0000-0001-7194-2693)
- Andrea Piccolini (ORCID: https://orcid.org/0009-0004-6601-1244)
- Stephan M. Korn
- Shahrokh F Shariat
- Klara Pohl (ORCID: https://orcid.org/0009-0001-6740-4005)
- Nicolai Hübner (ORCID: https://orcid.org/0000-0002-1256-1927)
Institutions
- Al-Ahliyya Amman University (JO)
- Boston University (US)
- Brigham and Women's Hospital (US)
- Humanitas University (IT)
- Harvard University (US)
- University of Pittsburgh (US)
- Medical University of Graz (AT)
- Cornell University (US)
- Charles University (CZ)
- Karl Landsteiner Society (AT)
- University College London (GB)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Journal of Endourology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1177/08927790251388065
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00